IART Quote, Financials, Valuation and Earnings

Intuitive Surgical has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of 28.41%. Integra Lifesciences Holdings's return on equity of -0.45% beat Intuitive Surgical's return on equity of 15.6%.

Integra Lifesciences Holdings has a consensus price target of $26.25, signalling upside risk potential of 21.02%. On the other hand Intuitive Surgical has an analysts' consensus of $624.78 which suggests that it could grow by 27.03%. Given that Intuitive Surgical has higher upside potential than Integra Lifesciences Holdings, analysts believe Intuitive Surgical is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.229, which suggesting that the stock is 22.861% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.616%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are smaller than Intuitive Surgical quarterly revenues of $2.4B. Integra Lifesciences Holdings's net income of $19.4M is lower than Intuitive Surgical's net income of $685.7M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Intuitive Surgical's PE ratio is 76.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.04x versus 21.32x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of 20.07%. Integra Lifesciences Holdings's return on equity of -0.45% beat LeMaitre Vascular's return on equity of 13.81%.

Integra Lifesciences Holdings has a consensus price target of $26.25, signalling upside risk potential of 21.02%. On the other hand LeMaitre Vascular has an analysts' consensus of $105.63 which suggests that it could grow by 27.18%. Given that LeMaitre Vascular has higher upside potential than Integra Lifesciences Holdings, analysts believe LeMaitre Vascular is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.229, which suggesting that the stock is 22.861% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.888, suggesting its less volatile than the S&P 500 by 11.173%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.82% to investors and pays a quarterly dividend of $0.20 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are larger than LeMaitre Vascular quarterly revenues of $55.7M. Integra Lifesciences Holdings's net income of $19.4M is higher than LeMaitre Vascular's net income of $11.2M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while LeMaitre Vascular's PE ratio is 42.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.04x versus 8.60x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of 26.88%. Integra Lifesciences Holdings's return on equity of -0.45% beat ResMed's return on equity of 25.56%.

Integra Lifesciences Holdings has a consensus price target of $26.25, signalling upside risk potential of 21.02%. On the other hand ResMed has an analysts' consensus of $270.09 which suggests that it could grow by 22.8%. Given that ResMed has higher upside potential than Integra Lifesciences Holdings, analysts believe ResMed is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.229, which suggesting that the stock is 22.861% more volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are smaller than ResMed quarterly revenues of $1.3B. Integra Lifesciences Holdings's net income of $19.4M is lower than ResMed's net income of $344.6M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while ResMed's PE ratio is 25.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.04x versus 6.59x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of -17.18%. Integra Lifesciences Holdings's return on equity of -0.45% beat Teleflex's return on equity of 1.57%.

Integra Lifesciences Holdings has a consensus price target of $26.25, signalling upside risk potential of 21.02%. On the other hand Teleflex has an analysts' consensus of $168.21 which suggests that it could grow by 22.07%. Given that Teleflex has higher upside potential than Integra Lifesciences Holdings, analysts believe Teleflex is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.229, which suggesting that the stock is 22.861% more volatile than S&P 500. In comparison Teleflex has a beta of 1.211, suggesting its more volatile than the S&P 500 by 21.134%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 0.99% to investors and pays a quarterly dividend of $0.34 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are smaller than Teleflex quarterly revenues of $795.4M. Integra Lifesciences Holdings's net income of $19.4M is higher than Teleflex's net income of -$136.7M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Teleflex's PE ratio is 97.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.04x versus 2.13x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.